ABSTRACT

BACKGROUND AND OBJECTIVES: Pro-inflammatory chemical mediators and algogenic substances seem to be confused by the sharing of their actions and by interactions in painful and inflammatory presentation. This study aimed at presenting a review of major inflammatory chemical mediators and place them in neuropathic pain pathophysiology.

CONTENTs: Inflammation is the homeostatic response of vascularized tissues to remove harmful agents and restore their normal functions. Nervous system (central and/or peripheral) diseases and injuries may induce neuropathic pain and may also modify inflammatory process nervous mediation. In such pathological conditions, there might be pain without restrict link with admittedly harmful or painful stimuli, as well as there might be inflammation without restrict link with the presence of harmful agents and the need to remove them. Chemical mediators involved in neuropathic pain and inflammation pathophysiology modulate the presentation of both.

CONCLUSION: Studies on inflammation offer evidences to support the important role of their chemical mediators in neuropathic pain pathogenesis. In peripheral and central sensitization, a thin borderline between reversibility or not of neuropathic pain may be respected or exceeded by inflammatory mediators actions. 

Keywords: Adenosine triphosphate, Bradykinin, Chemical mediators, Chemoattractants, Eicosanoids, Histamine, Inflammation, Neuropathic pain, Neurotrophic factors.

INTRODUCTION

Inflammation is a homeostatic response of vascularized tissues to remove noxious agents and restore their normal functions. Nervous system (central and/or peripheral) diseases and injuries may induce neuropathic pain and also change nervous inflammatory process mediation. In such pathological conditions, pain may appear without strict link with noxious or painful stimuli, as well as there may be inflammation without strict link with the presence of noxious agents and the need to remove them.

NP is fruit of imperfect regeneration of PNS and/or CNS. Inflammation is critical part of the attempt to restore tissue/cell and may be modulated by an intact or defective nervous system. Original cause of inflammation itself may or not be the same as that of NP and interaction of inflammatory and neuropathic processes shall inexorably occur.

According to its resolution time, inflammation may be acute or chronic. In acute inflammation, vascular changes result from the build up of fluids and polymorphonuclear cells at injury site. Migration of blood figured elements seems to be oriented by concentration of prostaglandins which would change the affinity of external chains of adhesion molecules receptors. Acute inflammatory responses may be systemic and include hyperthermia, leukocytosis, protein catabolism and liver plasma proteins synthesis, such as C-reactive proteins. Chronic inflammation has as characteristics cell infiltrate (lymphocyte and macrophage) and the simultaneous presence of injury and repair.

Pain is part of the first four classic signs of inflammation, together with blush, tumor and heat. Currently, they are recognized as elicited by a series of chemically mediated events, such as local vascular flow and patency changes, leukocytes infiltrate and algogenic substances release.

Most of the times, these phenomena lead to process resolution; however, in cases where inflammation evolves to chronicity, there might be tissue destruction and the appearance of the fifth and most deleterious inflammatory signal: function loss.

The inflammatory process is multimodal and sometimes even stereotyped, but it may show different responses as a function of noxious agent nature, of the predominant cell type of some infiltrates and of the participation of different chemical mediators.

PAIN AND SENSITIZATION

In general, pain is an unpleasant perception and a noxious sensation. Pain is not an isolated event, but rather a succession of linear and nonlinear events, which leads to a state of defensive hyperactivity, increasing the chance of detecting new styles and optimizing the defense system.

Pain is a symptom, a complaint. There is pain if there is its complaint. It is undoubtedly a verbal manifestation and in a broader sense corporal. Its presentation ranges from the so called silent receptors become active. There is global decrease in nociceptors thresholds.

Descritores: Bradicicina, Citocina, Dor neuropática, Eicosanóides, Fatores neurotróficos, Histamina, Inflamação, Mediadores químicos, Quimiocinas, Trifosfato de adenosina.

1. Fundação Antônio Prudente, Escola de Câncerologia Cefalino Boursoul, Departamento de Terapia Antitumoral, Curitiba, Próprio e Câncer de Palavras, São Paulo, SP, Brasil. 
2. Hospital de Magalhães, Serviço de Neurocirurgia, Porto Seguro, BA, Brasil. 
3. Hospital Alemão Oswaldo Cruz, Grupo de Dor, São Paulo, SP, Brasil.


Correspondence to: 
José Oswaldo de Oliveira Júnior 
Rua Pedroso Alvarenga, 1062, 5º andar (04531-004 São Paulo, SP, Brasil.
E-mail: jo.oliveirajr@yahoo.com.br

© Sociedade Brasileira para o Estudo da Dor

DOI 10.5935/1806-0013.20160045

Inflammatory mediators of neuropathic pain
Mediadores inflamatórios na dor neuropática
José Oswaldo de Oliveira Júnior1, Caio Sander Andrade Portella Junior2, Cláudia Panossian Cohen3


REVIEW ARTICLE

CONTENTS

INTRODUCTION

BACKGROUND AND OBJECTIVES: Pro-inflammatory chemical mediators and algogenic substances seem to be confused by the sharing of their actions and by interactions in painful and inflammatory presentation. This study aimed at presenting a review of major inflammatory chemical mediators and place them in neuropathic pain pathophysiology.

CONTENTs: Inflammation is the homeostatic response of vascularized tissues to remove harmful agents and restore their normal functions. Nervous system (central and/or peripheral) diseases and injuries may induce neuropathic pain and may also modify inflammatory process nervous mediation. In such pathological conditions, there might be pain without restrict link with admittedly harmful or painful stimuli, as well as there might be inflammation without restrict link with the presence of harmful agents and the need to remove them. Chemical mediators involved in neuropathic pain and inflammation pathophysiology modulate the presentation of both.

CONCLUSION: Studies on inflammation offer evidences to support the important role of their chemical mediators in neuropathic pain pathogenesis. In peripheral and central sensitization, a thin borderline between reversibility or not of neuropathic pain may be respected or exceeded by inflammatory mediators actions.

Keywords: Adenosine triphosphate, Bradykinin, Chemical mediators, Chemoattractants, Eicosanoids, Histamine, Inflammation, Neuropathic pain, Neurotrophic factors.

INTRODUCTION

Inflammation is a homeostatic response of vascularized tissues to remove noxious agents and restore their normal functions. Nervous system (central and/or peripheral) (CNS, PNS) diseases and injuries may induce neuropathic pain (NP) and also change nervous inflammatory process mediation. In such pathological conditions, pain may appear without strict link with noxious or painful stimuli, as well as there may be inflammation without strict link with the presence of noxious agents and the need to remove them.

NP is fruit of imperfect regeneration of PNS and/or CNS. Inflammation is critical part of the attempt to restore tissue/cell and may be modulated by an intact or defective nervous system. Original cause of inflammation itself may or not be the same as that of NP and interaction of inflammatory and neuropathic processes shall inexorably occur.

According to its resolution time, inflammation may be acute or chronic. In acute inflammation, vascular changes result from the build up of fluids and polymorphonuclear cells at injury site. Migration of blood figured elements seems to be oriented by concentration of prostaglandins which would change the affinity of external chains of adhesion molecules receptors. Acute inflammatory responses may be systemic and include hyperthermia, leukocytosis, protein catabolism and liver plasma proteins synthesis, such as C-reactive proteins. Chronic inflammation has as characteristics cell infiltrate (lymphocyte and macrophage) and the simultaneous presence of injury and repair.

Pain is part of the first four classic signs of inflammation, together with blush, tumor and heat. Currently, they are recognized as elicited by a series of chemically mediated events, such as local vascular flow and patency changes, leukocytes infiltrate and algogenic substances release.

Most of the times, these phenomena lead to process resolution; however, in cases where inflammation evolves to chronicity, there might be tissue destruction and the appearance of the fifth and most deleterious inflammatory signal: function loss.

The inflammatory process is multimodal and sometimes even stereotyped, but it may show different responses as a function of noxious agent nature, of the predominant cell type of some infiltrates and of the participation of different chemical mediators.

PAIN AND SENSITIZATION

In general, pain is an unpleasant perception and a noxious sensation. Pain is not an isolated event, but rather a succession of linear and nonlinear events, which leads to a state of defensive hyperactivity, increasing the chance of detecting new styles and optimizing the defense system.

Pain is a symptom, a complaint. There is pain if there is its complaint. It is undoubtedly a verbal manifestation and in a broader sense corporal. Its presentation ranges from the so called silent receptors become active. There is global decrease in nociceptors thresholds.

Descritores: Bradicicina, Citocina, Dor neuropática, Eicosanóides, Fatores neurotróficos, Histamina, Inflamação, Mediadores químicos, Quimiocinas, Tri fosfato de adenosina.
promote vascular patency dilatation and alteration, they cause flush, heat and edema, in addition to helping the detection of potentially noxious stimuli.

Among algogenic substances there are E prostaglandins which, for their potency and interaction with other substances as from minimum concentrations, have peripheral sensitizing effect and trigger nociceptors centripetal or orthodromic action potentials.4-5. Cytolysis offers cell membranes for degradation, which is another source of pro-inflammatory and algogenic substances. Its metabolites include prostaglandins and prostacyclines, leukotriens, tromboxanes, among others, which shall participate in the so-called "inflammatory soup."6-7. Nociceptors receive painful impulses and, after translating them, transmit to the second sensory neuron located in the gray matter posterior horn. Nociceptors interact with the medium when they are excited, producing and releasing special algogenic substances (pro-inflammatory), such as A and B tachykinins and substance P, a polypeptide related to calcitonin and somatostatin gene. These substances released in the interstitium are also spread by osmosis and act at a distance like other algogenic and anti-inflammatory mediators including bradykinin, eicosanoids (prostaglandins and leukotriens), adenosine triphosphate (ATP), histamin, pro-inflammatory cytokines (tumor necrosis factor, TNF, interleukin-1b and IFNy), chemokines (chemoattractant cytokine ligant 2, CCL2; fractalkine), neurotrophins (nerve growth factor, NGF; brain neurotrophic factor, BDNF) and oxygen reactive species.6-7. Building a biochemical trend of balance, many mediators such as immune cell-derived endorphins, anti-inflammatory cytokines (IL-10 and TGFb) and some neurotrophic factors (glial neurotrophic factor, GNF), show opposite effects to pain mediators.6-7.

General concept
Inflammatory chemical mediators are substances released in injured tissue or by adequately activated cells which coordinate the inflammatory response process. These are major determinants of the sequence of injured or ill nervous system neuroinflammation, and are major contributors to NP.0

DETAILS OF MAJOR INFLAMMATORY MEDIATORS INVOLVED WITH PAIN
Bradykinins
Bradykinin is a nonapeptide (peptide formed by nine aminoacids) of low molecular weight, from the vasoactive kinins family with short plasma half-life and low blood circulation levels. Bradykinins biological activity is mediated by two receptor pathways, called B1 (B1R) and B2 (B2R) receptors. Bradykinin activation of both receptors induces inflammation via pro-inflammatory cytokines release and increased vascular patency. Bradykinin B2 receptor is constitutively expressed by peripheral and central tissues, while B1 receptor is induced and regulated according to the evolution of infection, inflammation or trauma. In the nervous system, for example, B2 receptor is found, in normal situations, in different types of cells, including sensory neurons and microglial cells, while B1 receptor is sensitized in microglial cells, astrocytes and neurons after tissue injury.6-7. NP studies in animal models have shown that both bradykinin receptors play a hypersensitization role in pain. B2 alone contributes for the acute inflammatory and nociceptive response phase, while both B1 and B2 are important for the central NP process and transition to chronic pain.9,10. Bradykinins contribute to NP by sensitizing peripheral nociceptors terminals and potentiate spinal cord glutamaeric synaptic transmission.11. They also contribute to perpetuate cytokines and chemokines inflammatory cascade, as well as to stimulate histamine release by mast cells.6-7. Experimental intraplantar injections of B1 or B2 receptor agonists increase response to pain, while antagonists injection inhibits hyperalgesia in NP models.11. Decreased hyperalgesia secondary to nervous injury obtained by deleting the gene responsible for B1 receptors in mice confirms the important role of bradykinin as central inflammatory mediator in NP.12,13.

Adenosine triphosphate
The complex panel of purinergic systems and their importance in several pathophysiologic mechanisms is just recently emerging and generating scientific interest. The scientific community has resisted a long time until admitting that such a common metabolite as ATP could have actions going beyond its known participation in energetic metabolism.14,15. In fact, ATP is a multifunctional molecule also involved in signal transduction by cells. ATP, when released in the extracellular space after cell destruction, participates in the modulatory control of neuronal activity. Painful sensitivity mediation by the activation of ionotropic (P2X, ion channel)
and metabotropic (G protein-bound P2X) membrane receptors17. ATP may help pain transmission by some mechanisms: activation of C fibers receptors causing increased axonal peripheral nerve sensitivity; activation of primary afferent pathway in spinal cord pre-synaptic terminal; and induction of pain mediators release such as BDNF and glial pro-inflammatory cytokines to activate and sensitize nociceptors6. NP models in which the application of A-317491, P2X3 and P2X2/3 receptor antagonists or with treatment with oligonucleotide of reverse P2X3 sense, cause decrease in dorsal root ganglion protein expression (DRG) and spinal cord, which attenuates both thermal hyperalgesia and mechanical allodynia in rats with peripheral nerve injury, indicating action of P2X3 receptor on NP. P2X4, P2X7 and P2Y12 receptors expressed in the microglia appear as having new and important role in NP etiology. Their activation by ATP is related to microglial response to peripheral nerve injury which contributes for the hyperexcitability of spinal dorsal gray matter and for NP symptoms.

Spinial microglial activation is a major pathologic process, occurs less than four hours after peripheral nerve injury and is strongly correlated to pro-inflammatory cytokines release and hyperalgesia6. Recent pharmacological, genetic and behavioral studies have shown that purinergic P2X4 receptors are necessary and sufficient for NP. Their expression is increased in spinal microglial cells after nervous injury and spinal administration of these cells previously stimulated by ATP in animals induces alldynia similar to that caused by peripheral nerve injury14,15. The mechanism by which P2X4 microglial receptor stimulation produces NP involves phenotypic electrophysiologic changes in spinal cord dorsal horn lamina I neurons. The activation of these receptors promotes BDNF release, which causes dorsal horn neuronal disinhibition by interrupting homeostasis of intracellular chloride ion. P2X4 may safely be considered a major mediator of neuron-microglia signalling and its blockade reverts hyperalgesia. The activation of P2X7 receptors in immune cells (mast cells, macrophages, T lymphocytes and microglia) induces fast activation and secretion of interleukin 1β (IL-1β)21. Rats treated with P2X7 antagonist show decreased hypersensitivity to pain, while sensitization of P2X7 receptors is detected in DRG and in peripheral nerves of NP patients15. The activation sequence coding P2X7 receptors affects the formation of pores, promoting sensitivity to chronic pain both in rats and in humans, indicating the possibility of a new strategy to control chronic pain22.

P2Y12 receptors also activate microglia and contribute to NP. The activation of these receptors promotes the involvement of microglial cells with myelinated axons in spinal dorsal gray matter24. The inhibition of these same receptors by P2X12 antagonists or genetic deletion of gene P2ry12 relieves hyperalgesia in animal NP models24. The P2X12 receptor antagonist, clopidogrel, is clinically used to prevent the formation of blood clots, which may speed the screening of therapeutic agents in NP. So, purinergic system is a promising set of therapeutic targets to control nociceptive and inflammatory NP processes.

Eicosanoids

Eicosanoids are a numerous family of compounds with high potency and broad biological activity spectrum. These are long-chain polyunsaturated fatty acids oxygenation products. One of these acids, the arachidonic acid, constituent of cell membranes, is the most abundant and important precursor of eicosanoids. Cleavage (also known as release or mobilization) of cell membranes arachidonic acid, which makes this fatty acid of 20 carbons amenable to oxygenation. Although cleavage may happen without cell death, it is in injury and degeneration that there is higher availability for the acid to be metabolized; and so, its metabolites become indicators of noxious or potentially noxious stimuli15-22.

Arachidonic acid oxygenation is documented in four different pathways: that catalyzed by cyclooxygenases (COXs), that by lipoxigenases, that by epoxygenase and the isoprostane pathway. After being cleaved from cell membrane by phospholipase A2, arachidonic acid may be converted into prostaglandins by cyclooxygenases (COXs) or into leukotriens (LTs) by lipoxigenases.

Products of endoperoxide synthase enzymes (cyclooxygenases or COXs)

COXs pathway consists of the action of at least two enzyme isoforms:

1. COX-1 and COX-2.
   - COX-1 is found in most tissues, promoting homeostasis (although its expression may be high after cell trauma); while COX-2, the expression of which at rest is low, is rapidly increased by the action of inflammatory mediators (cytokines) after injury.
   - Prostaglandins PGE2 and PGD2 are major COXs pathway products and are predominantly activated by PE receptors (PE1-4 to PGE2 and PGI receptors to PGD2). These prostaglandins activate sensory afferent fibers and promote spinal cord nociception by depolarization of WDR-type neurons and block neuronal injury by glycine. COX-2 and PGD2 expressions drastically and slowly (months) increase after nervous injury both in injury site and spinal cord. Non-selective COX, COX-2 inhibitors and PE1 antagonists locally or intrathecally, relieve hypersensitivity to pain in NP models. Clinical observation repeated in animal models considers macrophages infiltration as major source of COX-2 after nervous injury and has shown that PE1 receptors expression in macrophages is also abnormally increased, suggesting a vicious inflammatory cycle.
   - E2-type prostaglandin has been recently related to increased production of pro-inflammatory cytokines, IL-6 and neutrophic factors, BDNF, in DRG nervous injuries, in addition to contributing for the medium of pain mediators22-27.

2. Purinergic P2X4 receptors are necessary and sufficient for NP. Their activation by ATP is suggested above and decreases hyperalgesia resulting from LTB4-induced hyperalgesia. Zafirlucaste, cisLTs antagonist, decreases pain hypersensitivity in inflammatory pain models.

Lipoxygenase products

Arachidonic acid metabolism is also catalysed by lipoxigenases (LOXs): 5-, 12- and 15-lipoxigenase producing hydroxyeicosatetraenoic acids (HPETE) which in turn are rapidly converted in hydroxy derivatives (HETE) and leukotriens. The interest on lipoxygenase pathway, also known as allergic inflammation pathway, is to better understand and improve the management of asthma, anaphylactic shock and cardiovascular disease.

Leukotriens (LTs) are a group of lipid chemical mediators formed by the insertion of oxygen in different positions inside arachidonic acid. 5-lipoxigenase (5-LOX), enzyme present in inflammatory cells (leucocytes, polymorphonuclear, basophils, mast cells, eosinophils and macrophages) catalyses LTD4 formation which, together with its metabolites (LTB4, Ciseinill LTs or cistLTs, LTC4, LTD4 and LTE4) are the most widely studied28-29.

The activation of these inflammatory cells induces increase in calcium free ions in respective cytoplasms and releases arachidonic acid for oxygenation by 5-LOX (in turn activated by its own activating protein 5-LOX FLAP) which produces an unstable intermediate epoxy-type substance, leukotrien A4 (LT4). At this point, epoxide may be converted into dihydroxy leukotrien B4 (LBT4) or suffer conjugation with glutadione. In conjugation there is formation of leukotrien C4 (LTC4), which suffers the action of different peptidases in its recently conjugated portion (a true sequential degradation) forming LTD4 and LTE4. The latter products and C4 are called cistelin leukotriens or peptideleukotriens.

LTs action on specific receptors for LT in the surface of many immune and glial cells: BLT1 is receptor with affinity for LTD4, while BLT2 has lower affinity for LTD4 and other LTs; CisLT1 and 2 are selective receptors30. LTB4 exerts strong chemotaxis on neutrophyls expressing BLT (1 and 2). Intraplatant LTB injections produce hyperalgesia by inducing the release of other leukotriens (9R and 15S-diHETE), which sensitize nociceptors and may contribute for NP. The inhibition of 5-LO confirm the findings commented above and decreases hyperalgesia resulting from LTB4-induced NGF release4-6.

Zafirlucaste, cistLTs antagonist, decreases pain hypersensitivity in inflammatory pain models30. In models of peripheral nerve injury-induced NP, there are activated spinal microglial populations. Recent studies have shown that these microglial cells have increased expression of 5-LO and cistLTs, together with increased BLT1 receptors30. Closing the set of evidences on the role of such inflammatory chemical mediators on NP, intrathecal application of 5-LO inhibitors (BLT1 antago-
Histamine

Histamine is a biogenic endogenous amine which mediates pleiotrophic effects by means of four different subtypes of receptors bound to G proteins, called H1 to H4, which are expressed in different manners in each cell type. In humans, histamine is a major mediator of immediate and inflammatory allergic reactions, although playing a modest role in anaphylaxis. With complex physiologic and pathologic effects causing broad effects, part of them undesirable, histamine has never been adopted as drug to treat diseases, giving place to selective agonists or antagonists of some subtypes of its receptors.

Classic source of histamines are mast cells, where they are stored in cytoplasmic granules and released by exocytosis to exert several actions in response to different stimuli. Histamine not coming from mast cells derives from multiple sources, such as circulating leukocytes (especially eosinophils, although in concentrations ten times lower) and neurons. Gastric cells producing histamine are called histaminocytes and in the central nervous system they are called histaminergic neurons. It is believed that mast cells degranulation in the nervous system is triggered by tissue injury or by increased adenosine or bradykinin in response to mechanical injury30.

Immune processes are the most important mechanism of histamine release by mast cells and basophils. These cells, when sensitized by IgE antibodies fixed to its surface, respond to antigens with histamine and/or other mediators release (by citolysis or exocytosis).

Once released, histamine is able to sensitize nociceptors resulting in hyperalgesia. Treatment with mast cells stabilizer chromolyn, prevents the development of hyperalgesia, partially secondary effect of lower histamine release31. Local treatment of injured nerve with H1 and H2 receptor antagonists relieves hyperalgesia. Mild analgesia of anti-histaminics is clinically proved. recent studies confirmed the hypothesis that systemic histamine 60H increases BDNF synthesis and activity6.

Another mechanism of spinal treatment with GDNF reverts NP by means of decreased astrocytes activation in spinal cord posterior horn 32. Chemokines, other cytokines and their receptors are broadly expressed in different sites 33. In the second pathway, BDNF is released in the trigeminal ganglion by activity-dependent TNF pathway 34. Spinal treatment with GDNF reverts NP by means of decreased astrocytes activation in spinal cord posterior horn after nervous injury 35. Chemokines are a large family of structurally homologous cytokines with chemotaxis capacity, which orient migration of leukocytes to the injury site. Chemokines, other cytokines and their receptors are broadly expressed in different sites 36.
pressed in the central nervous system and there are increasing evidences of their action on NP. There are many inflammatory cytokines involved in NP models, such as IL-1β, TNF, IL-6, IL-15, IL-17, IL-18 and INF-γ, while anti-inflammatory cytokines, such as IL-4, IL-10 and TGF-β have analgesic action. Immune homeostasis is normally maintained by endogenous anti-inflammatory cytokines release, particularly IL-10, which makes negative feedback when suppressing genes coding pro-inflammatory cytokines and their receptors. However, if the central nervous system is injured, there is release of IL-1β, TNF and IL-6 and there is positive feedback to activate inflammatory cascades. Many pro-inflammatory cytokines indirectly contribute to pain due to their ability to potentiate the production of algogenic mediators such as PGE-2. Interaction is narrowed when the effect on the affinity state of external anchorage of adhesion molecules of blood figured elements are studied. There is strong evidence of the direct action of some cytokines on receptors present in nociceptors. Cytokines, including chemokines released after nervous injury, may modulate spinal blood-spinal cord barrier patency by increasing IL-1β and CCL2 circulation. Spinal infiltration of immune cells is related to cytokines release.

The balance between pro and anti-inflammatory cytokines after nervous system injury is essential both for its own recovery and the development of NP. Patients with complex regional pain syndrome, painful neuropathy and spinal injury have systemic increase of TNF and IL-6 pro-inflammatory cytokines release, in addition to levels of anti-inflammatory cytokines such as IL-10 and IL-4, while those with painless neuropathy have increased levels of anti-inflammatory cytokines. Cytokines modulation when blocking pro-inflammatory cytokines and/or increasing anti-inflammatory cytokines is effective to control pain and brings to light the discussion about the effects of cytokines on NP.

**Pro-inflammatory cytokines**

**Tumor necrosis factor**

Tumor necrosis factor (TNF) is probably the most widely studied pro-inflammatory cytokine and acts by two receptors: constantly expressed TNFR1 and inducible TNFR2. TNF starts several signalling pathways: activates nuclear factor (NF)-KB, which induces transcription of pro-inflammatory cytokine coded genes, thus triggering an inflammatory cascade. Several animal studies confirm the role of TNFs in neuropathic pain, however, actions of TNFR1 and TNFR2 receptors are still not totally explained. Behavioral, pharmacological, and electrophysiologic studies confirm the significant contribution of TNF to peripheral and central nervous system sensitization. When TNF is applied to healthy sciatic nerve and DRG (dorsal root ganglion) there are ectopic firings of Aδ, Aβ and C fibers, thus decreasing mechanical threshold needed to activate C fibers. After nervous system injury, endogenous TNFs are launched by mast and Schwann cells, which are followed by a second wave of TNFs launched by neurogenic infiltrates and macrophages. Elevation of TNFs is correlated to pain and hypersensitivity. TNF increases vascular patency in hairless skin increasing leukocytes infiltration and consequently inflammatory response. These effects support the theory which suggests that TNFs are peripheral sensitizers. Nervous injuries also trigger increased TNF in spinal cord dorsal part, which increases NAV 1.3 and NAV 1.8 sodium channels expression, as well as increases post-synaptic excitatory chain by means of NMDA and AMPA receptors, both susceptible to central sensitization. The interference of TNF signalling using neutralizing antibodies or antagonists of their receptors may attenuate NP. In the last decade, treatment with anti-TNF (infliximab, etanercept) has positively transformed the treatment of severe inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel diseases and psoriasis. These drugs are effective to revert hyperalgesia in painful rat models and in rats with neuropathic pain due to nervous injury.

**Interleukin-1β**

Interleukin-1β is the second more important pro-inflammatory cytokine which, when applied to healthy nerves, dorsal roots ganglia and dorsal spine decrease activation threshold and promote spontaneous firings of action potential, thus causing pain and hypersensitivity. Close to a peripheral nervous injury, IL-1β is rapidly released by Schwann cells, as well as by local macrophages and infiltrates. In spinal cord, nervous injury activates microglial and astrocytary cells and this activation results in a 15-fold increase in the levels of IL-1β, effect totally reverted with glial inhibitor propentophelin, which also normalizes pain and hypersensitivity. Pain worsening mechanism of IL-1β includes: reinforcement of voltage-dependent sodium channels in painful receptors by “p38” pathway; increased excitatory chains by means of NMDA and AMPA receptors phosphorylation; and spontaneous decrease of GABA and current-inhibiting glycine on spinal cord. There is analgesic effectiveness on IL-1 receptors block or interfering with IL-1β signalling via neutralizing antibodies in NP models. IL-1 antagonist anakinra was clinically approved for rheumatoid arthritis and may be also beneficial for NP patients. A recent study has stressed IL-1β potential on nervous regeneration since it has been shown that IL-1β in rats elicits evident losses in injured nerve function recovery. The therapeutic possibility comes from the probable ability of blocking such interleukin.

**Interleukin-6 (IL-6)**

In general, IL-6 has pro-inflammatory activity, however in some circumstances it may be modulator and induce anti-inflammatory response. With peripheral nerve injury, IL-6 is released by Schwann cells and macrophages, as well as by neurons and glial cells in DRG and spinal cord. IL-6 predominantly appears in the cascade with TNF and IL-1, however, which comes first is still questionable. IL-6 role on acute nociceptive pain modulation is contradictory and its peripheral application in animals causes algiic and antalgie effects. In laboratory NP models it is obvious the ability of IL-6 to promote pain when rats with genetic deletion of this interleukin are treated with its neutralizing antibody and there is decrease in nervous injury-induced pain. After nervous injury, IL-6 increases pain responses of mediators such as BDNF and substance P, which promote neuronal excitation. All cytokine receptors share the same architectural project which involves a large extracellular domain exposed for connection with specific ligand (cytokine) and, united by a single transmembranous helix, an intracellular domain. In case of interleukin-6, response induced by its ligation in the external domain starts with dimerization of receptor which attracts one unit of tyrosine kinase cytosolic (Jak) to associate and then phosphorylates receptor’s dymer. Phosphorylation target in the internal domain of IL-6 receptor is a specific protein of the transcription factors family (Stats). The specific stat is bound to phosphotyrosine grouping of receptor-Jak complex, being itself phosphorylated. Phosphorylated Stat migrates toward cell nucleus and activates genic expression and promotes nervous injury by microglia activation in spinal cord dorsal region. Analgesic therapeutic possibility arouses from the blockade of this pathway with expected decrease of neuroinflammation diffusion in spinal cord and pain and hypersensitivity attenuation. In healthy humans, IL-6 levels are very low, but they may increase during painful inflammatory conditions. Antibodies anti-IL-6 (tocilizumab) have been approved for RA and a recent study has shown tocilizumab effectiveness to treat radicular pain and low back pain caused by spinal stenosis. Further clinical trials are needed to evaluate direct effects on NP of IL-6 inhibition.

**Other inflammatory cytokines**

Another pleiotropic cytokine, IFN-γ, has been associated to chronic pain as from its application. IFN-γ may cause neuronal sensitization and trigger spontaneous firings, as well as decreased inhibitory tone. IFN-γ is also associated to microglial cells activation, and so IFN-γ signalling ablation prevents microglial activation as well as the development of pain and hypersensitivity after nervous injury. IFN-γ signaling with microglia induces over-stimulation of several proteins, such as purinergic receptors P2x4 and kinase receptor CCR2 which contribute for NP onset. Analgesic properties of canabinoid receptor agonists (CBR2) are associ-
ated to reversible inhibition of microglial cells in activating IFN-γ signaling60. In general, INF-γ are involved with NP pathogenesis, especially by a central effect on neurons and microglia.

IL-15 are expressed in damaged neurons and in macrophage infiltrates of injured nerves, as well as in reciprocity in spinal cord macrophages and reactive microglial cells. These are involved in NP development by promoting macrophages and T cells at nervous injury side and spinal cord61. IL-17 is a pro-inflammatory cytokine predominantly produced by Th17 cells, but also by neutrophils, cytotoxic T cells and glial cells and has an important role in nervous system inflammatory disorders such as multiple sclerosis62.

IL-17 administration in laboratory rats has induced pain behavior63. After nervous injury, IL-17 increases nervous degeneration with peak around the seventh day and is found in T cells of the injured nerve62.

Pain and hypersensitivity are decreased in rats with Rag type 1 deficiency (family of restriction endonuclease enzymes which cleave DNA by recognizing the site by the identification of bases pairs sequences) in T cells, with failure in IL-17 and IL-17 expression in rats64,65. This effect decreases both T cells and macrophages infiltrate in sciatic nerve decreasing spinal cord glial activity65. This way, there are increasing evidences that IL-17 is involved in NP maintenance.

IL-18 is member of IL-1 cytosines family, which are expressed in chronic inflammation and are activated by IL-18 receptors (IL-18R). These are expressed by astrocytes peak seven days after nervous injury. However, neutralizing antibodies against IL-18 and IL-18R only partially decrease both pain development and maintenance/stabilization66. The factor also promotes in these same conditions decreased activation of microglial cells and astrocytes, as well as decreased chemokine CCL2 expression. IL-10 and IL-18 may increase blood-spinal cord barrier (BSCB), thus decreasing additional infiltration of immune cells in the dorsal horn. Bone morphogenetic protein and activin membrane-bound inhibitor (BAMBI) are natural inhibitors of the tumor growth factor family. Animals with genetic BAMBI deletion have increased activated TGF-β levels and decreased acute pain, as well as NP induced by nervous injury67.

Antinociceptive TGF-β effect may also involve the opioid system since precursor proteins of endogenous opioids have also shown increase in spinal cord of the same mice with deletion of genes responsible for BAMBI68. TGF-β seems to activate glial suppression, to inhibit pro-inflammatory cytokines release and to promote endogenous opioids analgesia expression.

Modulation of these anti-inflammatory cytokines deserves investigation as therapeutic potential for neuropathic pain and chronic pain in general.

**ANTI-INFLAMMATORY CYTOKINES**

**Interleukin-10**

Interleukin-10, released by activated T cells, B cells, macrophages and mast cells, is a powerful anti-inflammatory cytokine, inhibiting cytokines, IL-1b, IL-6 and TNF release61. If the catabolic flow is compared to a river flow, substances to be triggered would be at the source while their final metabolites would be at its mouth. In this context, IL-10 suppression mechanisms downstream to its receptor, occur by SOCS3m induction which, in turn, inhibits genes normally activated by JAK-STAT3 pathway, as well as by NF-kB pathway inhibition69. After nervous injury, IL-10 expression rapidly increases (1 hour) in the injured area and in up to 24 hours in DRG. Spinal and interneuron IL-10 may significantly attenuate hypersensitivity of nerve injury-induced pain, associated to decreased infiltration by immune cells and decreased IL-1b and adenosine expression70. Adenosine receptor reverse agonists 2A and CBR2 stabilize hypersensitivity pathway of pain induced by IL-10 release69,70. IL-10 has analgesic effects due to its ability to inhibit pro-inflammatory cytokines.

**Interleukin-4 (IL-4)**

Interleukin-4 is a prototypic anti-inflammatory cytokine released by activated mast cells and some T cells populations. It is able to inhibit most inflammatory cytokines and may suppress macrophages and microglial cells activation. Previous treatment of nerves with IL-4 may desensitize them to responses to painful stimuli induced by knowingly algogenic substances (pro-inflammatory mediators), such as bradykinins and TNF6. IL-4 in knockout rats (+/-) without nervous injuries induces increased sensitivity to mechanical stimulation and, surprisingly, this interleukin in wild rats (with intact genetics) nervous injuries still do not show increased pain hypersensitivity as compared to wild types71. This discrepancy seems to be due to the fact that IL-4 in rats with overcompensation of the expression of other anti-inflammatory cytokines, such as IL-10 and IL-13.

Both nervous injury stabilization and maintenance phases have induced pain hypersensitivity which has been decreased by genes IL-4 therapy, which is associated to decreased spinal release of IL-1b and PGE2, as well as decreased in p38 MAPK phosphorylated, indicative of decreased number of activated microglial cells62. Some IL-4 analgesic effects also occur by the positive regulation pathway of m e d opioids63.

**Tumor growth factor-beta (TGF-β)**

TGF-β has a wide variety of immune functions, although being considered an immunosuppressant. TGF-β deeply induces lymphocytes proliferation and cytokines production, influences T cells differentiation and promotes regeneration of T immunosuppressant-regulating T cells. After peripheral nerve injury, spinal TGF-β significantly attenuates both pain development and maintenance/stabilization72. The factor also promotes in these same conditions decreased activation of microglial cells and astrocytes, as well as decreased chemokine CCL2 expression. TGF-β and IL-10 may increase blood-spinal cord barrier (BSCB), thus decreasing additional infiltration of immune cells in the dorsal horn. Bone morphogenetic protein and activin membrane-bound inhibitor (BAMBI) are natural inhibitors of the tumor growth factor family. Animals with genetic BAMBI deletion have increased activated TGF-β levels and decreased acute pain, as well as NP induced by nervous injury73. Antinociceptive TGF-β effect may also involve the opioid system since precursor proteins of endogenous opioids have also shown increase in spinal cord of the same mice with deletion of genes responsible for BAMBI70. TGF-β seems to activate glial suppression, to inhibit pro-inflammatory cytokines release and to promote endogenous opioids analgesia expression.

Modulation of these anti-inflammatory cytokines deserves investigation as therapeutic potential for neuropathic pain and chronic pain in general.

**Chemokines**

Chemokines are known as chemo-attractant (or chemo-attractive) cytokines which control leukocytes migration acting as coordinators of cellular traffic during immune and inflammatory reactions. Chemokines and their receptors are important in inflammatory nervous system diseases for mediating leukocytes within nervous inflammation areas.

In fact, there is a slight conflict in naming and classification adopted already consecrated by custom, since some mediators which are not cytokines also control leukocytes movement and many true cytokines are not restricted to this function.

More than forty chemokines have been identified and their classification may be simplified in two groups, taking into consideration whether primary cysterin residues of the polypeptide chain are adjacent (chemokines C-C) or separated by other residue (C-X-C). The former are implied in chronic presentations and the latter in acute presentations.

Major nervous system cell types, such as neurons, glia and neural parent cells, express several chemokines and their receptors.

Evidences gathered on chemokines show involvement of neural migration and cell proliferation during brain development, synaptic transmission modulation, neurodegenerative diseases and pain8. When related to NP, chemokines production leads to higher sensitivity to pain both indirectly by the attraction of leucocytes and indirectly by nociceptive neurons excitation.

Chemokines and their receptors were implied in NP. Two most important pairs (ligant + receptor) are commented below.

**CCL2 (MCP-1)/CCR2**

The expression of CCL2 cytokine and its respective receptor (CCR2) on neurons and glial cells in DRG is already well documented8,9. Using an NP model of chronic DRG compression, it was shown increased CCR2 and CCL2 expression both in injured and healthy (without compression) neurons. The application of CCL2 in injured sensory nerves in vivo produces potent excitatory effects8. After sciatic nerve injury, similar findings of increased expression of CCL2 in DRG neurons and within endoneuron are evident8.

However, CCL2/CCR2 expression in spinal cord is controversial. Several evidence lines show that CCR2 constitutively occurs in spinal cord
neurons and become hyperactive after nerve injury75. CCL2/CCR2 signaling in spinal cord is a critical point for the activation of spinal glia, and there is possibility of this chemokine produced in DRG to be transported to proximal terminations of such pseudo-unipolar glia in gray matter dorsal portion. Intrathecal administration of CCL2 neutralizing antibodies in animals with nerve injury has shown decreased microglia activation and pain behavior inhibition76. Confirming such findings, rats without CCR2 have shown little NP after nerve injury, resulting from decreased macrophages infiltration, spinal glia cells activation and decreased neuronal sensitization77. CCR2 activation on DRG neurons and CCL2 release in spinal cord nervous system contribute to increased nociceptive neurons excitation and NP promotion. CCR2 antagonists may have therapeutic value in the future78-79.

CX3CL1 (fractalkine)/CX3CR1
Fractalkine is a cytokine expressed in the external surface of spinal neuron cells and of spinal cord sensory afferents80. In spinal cord dorsal part, fractalkine receptors are primarily expressed by microglia and are over-expressed after nerve injuries18.

CX3CL1/CX3CR1 expression pattern suggests their involvement in neuronal signaling and spinal cord microglia. Binding of CX3CL1 and CX3CR1 activates P38 MAPK inducing microglial activation and pro-inflammatory cytokine synthesis, such as TNF, IL-1β and IL-66. This, in turn, contributes to synapses plasticity and spinal cord neuronal activation. Behavioral studies have shown that spinal fractalkine produces dose-dependent pain and hypersensitivity, while neutralizing CX3CR1 antibodies injection delays and decreases nociceptive response in NP models87.

CX3CR1 blockade in rats decreases pain and hypersensitivity with decreased spinal glial activation after peripheral nerve injury88. Evidence suggests that CX3CL1 (CX3CR1) release by neurons in response to injury or to an inflammatory mediator induces glial activation and pain facilitation.

CONCLUSION
There is increasing production of evidences obtained by pre-clinical trials showing that inflammatory mediators play critical roles in NP pathogenesis. In peripheral nervous system, inflammatory mediators are hyper-regulated by resident cells and infiltrate leucocytes after peripheral nerve injury, to induce peripheral sensitization. In central nervous system, in spinal cord, inflammatory mediators broadly contribute to glial cells activation after nerve injury, inducing central sensitization. Modulation and intensional direction of these mediators inhibiting pro-inflammation and increasing anti-inflammatory mediators, may be considered important therapeutic strategies for NP. However, recent scientific production also cautions for the difficulty to translate results obtained in this animal research field into application in humans.

REFERENCES
23. Sorge RE, Tsang T, Dorfman R, Smith SB, Begg S, Ritchie J, et al. Genetically determined P2X7 receptor expression in spinal cord regulates cellular migration and inflammation and increasing anti-inflammatory mediators, may be considered important therapeutic strategies for NP. However, recent scientific production also cautions for the difficulty to translate results obtained in this animal research field into application in humans.
